Arca
Skip to content

BLA 761311: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761311's history or Galderma R&D, LLC's company page.

On Sep 29, 2023, FDA declined to approve BLA 761311 (BLA 761311) from Galderma R&D, LLC in its present form, citing product quality. openFDA lists it as not yet approved.

  • Letter date: Sep 29, 2023
  • Application: BLA 761311
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Product quality

The Letter

Text from openFDA; FDA's scanned original (PDF) ↗

Dear Chase Edwards:

Please refer to your biologics license application (BLA roccived or relabotulinumtoxin A injection.

We also acknowledge receipt of your amendment dated ee. which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter.

We have completed our review of this application and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

PRODUCT QUALITY

Microbiology

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Drug substance product quality Manufacturing Process

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Characterization

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Process Validation and Evaluation

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Leachables and extractables

Cell banks requalification

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Specifications

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Reference Standards

Drug product quality

Process Validation and/or Evaluation

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Reference Standards or Materials

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Stability

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) - a checklist of important format items from labeling regulations and guidances.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format as described at FDA.gov.3

CARTON AND CONTAINER LABELING

We reserve comment on the proposed labeling until the application is otherwise adequate.

MEDICATION GUIDE

(1) Add the following bolded statement or appropriate alternative to the carton and container labeling per 21 CFR 208.24(d): "ATTENTION PHARMACIST: Each patient is required to receive the enclosed Medication Guide."

PROPRIETARY NAME

Please refer to the correspondence dated, oe in which your proposed proprietary name, was found unacceptable. If you intend to have a proprietary name for this product, resubmit a new request for a proposed proprietary

1 https:/Awww.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources

2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs- final-rule

$ http://www. fda.gov/Forlndustry/DataStandards/StructuredProductLabeling/default.htm

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov name review when you respond to all of the application deficiencies that have been identified in this letter. You may also submit a Request for Proprietary Name Review to your IND in the interim.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

(1) Describe in detail any significant changes or findings in the safety profile.

(2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:

e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.

e Present tabulations of the new safety data combined with the original application data.

e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above.

e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials.

(3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified.

(4) Provide case report forms and narrative summaries for each subject who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.

(5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.

(6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

(7) Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov (8) Provide English translations of current approved foreign labeling not previously submitted.

ADDITIONAL COMMENTS

We have the following comments/recommendations that are not approvability issues.

PRODUCT QUALITY

Microbiolo

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Drug Substance:

Cell banks characterization

Manufacturing process development

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Manufacturing Process

Future cell banks qu ation protocol

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Facility Inspection

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 601.3(b). If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under

21 CFR 601.3(c). You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products.

The product may not be legally marketed until you have been notified in writing that this application is approved.

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Wow awe ey ene,

Sincerely,

{See appended electronic signature page}

Center for Drug Evaluation and Research

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Signature Page 1 of 1

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

(b) (4)

09/29/2023 03:16:27 PM

Other Letters on This Application

Record

Company
Galderma R&D, LLC
Application
BLA 761311
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.